Open house Arzneimittelrabattverträge Vildagliptin, ATC A10BH02
Oryginalny tytuł ogłoszenia
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Vildagliptin, ATC A10BH02
Ocena szansy
Skąd ta ocena?
Szansa
55 / 100
Złożoność
20 / 100
Czynniki ryzyka
The open-house agreements automatically expire if a competitive rebate contract (national or regional) for Vildagliptin...
The agreements are non-exclusive and do not ensure any sales volume; they only provide a rebate framework. Actual sales...
Głęboka analiza portfolio
Wykorzystuje:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Przegląd
Strong opportunityKluczowe fakty
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Nov 2026
- Non-exclusive rebate agreements for Vildagliptin (ATC A10BH02) for AOK Bayern.
- All eligible pharmaceutical companies can participate; no selection process.
Pokaż pełne podsumowanie
AOK Bayern is implementing a non-exclusive open-house model for pharmaceutical rebate agreements for the active ingredient Vildagliptin (ATC A10BH02) under §130a Abs. 8 SGB V. All qualified pharmaceutical companies can enter into identical, non-negotiable rebate agreements. The earliest contract start is 01.12.2024, all agreements end 30.11.2026. Joining is possible any time until 05.10.2026. The procedure is not subject to public procurement law; it is a voluntary open-house model with no selection of contractors. Only pharmaceutical companies are eligible. Submission requires a signed self-declaration of reliability and the signed contract with annex. Documents can be submitted in paper (2 copies) or electronically with qualified electronic signature. The buyer is AOK Bayern. No estimated value is provided. Award criteria are not applicable as all eligible participants are accepted.
Ryzyka
The open-house agreements automatically expire if a competitive rebate contract (national or regional) for Vildagliptin...
The agreements are non-exclusive and do not ensure any sales volume; they only provide a rebate framework. Actual sales...
Analiza może być niepełna
Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.
Kluczowe wymagania
Technical
- Signed contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel' required.
Eligibility
- Only pharmaceutical companies are eligible (potential contractors).
Administrative
- Signed self-declaration of reliability must be submitted.
Zamawiający
Lokalizacja
München, DEU
Strona
Profil zamawiającego
Identyfikator
DE811695320
Działalność
Health
Części (1)
LOT-0001
Open house Arzneimittelrabattverträge Vildagliptin, ATC A10BH02
Open-house model for non-exclusive rebate agreements for Vildagliptin (ATC A10BH02) to be concluded with any interested pharmaceutical company that meets the eligibility criteria. Agreements are identical and non-negotiable. Contract period: 01.12.2024 to 30.11.2026.
Lokalizacja
Czas trwania
Kategoria
Termin
Szczegóły kryteriów
Siehe kurze Beschreibung
Uwaga do wartości
Pokaż oryginalne dane TED
Oryginalny opis TED
Siehe kurze Beschreibung
Szczegóły zamówienia
- Data publikacji
- 16 Oct 2024
- Języki
- German
Metadane referencyjne
- Podstawa prawna
- 32014L0024
Identyfikatory referencyjne
- ID przetargu
- 628246-2024
Dokumenty (2)
Podobne przetargi
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Ocena szansy
Skąd ta ocena?
Szansa
55 / 100
Złożoność
20 / 100
Czynniki ryzyka
The open-house agreements automatically expire if a competitive rebate contract (national or regional) for Vildagliptin...
The agreements are non-exclusive and do not ensure any sales volume; they only provide a rebate framework. Actual sales...
Głęboka analiza portfolio
Wykorzystuje:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications